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In Brief
Yeo et al. demonstrate that p53 maintains
genomic stability during replication by
preventing the interference between
replication and transcription.
Transcription inhibition restores fork
progression and attenuates the
sensitivity to Topo II inhibitors in p53-
deficient cells, providing compelling
evidence that transcription causes
chronic replication stress in the absence
of functional p53.
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p53 tumor suppressor maintains genomic stability,
typically acting through cell-cycle arrest, senes-
cence, and apoptosis. We discovered a function of
p53 in preventing conflicts between transcription
and replication, independent of its canonical roles.
p53 deficiency sensitizes cells to Topoisomerase
(Topo) II inhibitors, resulting in DNA damage arising
spontaneously during replication. Topoisomerase
IIa (TOP2A)-DNA complexes preferentially accumu-
late in isogenic p53 mutant or knockout cells, reflect-
ing an increased recruitment of TOP2A to regulate
DNA topology. We propose that p53 acts to prevent
DNA topological stress originating from transcription
during the S phase and, therefore, promotes normal
replication fork progression. Consequently, replica-
tion fork progression is impaired in the absence of
p53, which is reversed by transcription inhibition.
Pharmacologic inhibition of transcription also attenu-
ates DNA damage and decreases Topo-II-DNA com-
plexes, restoring cell viability in p53-deficient cells.
Together, our results demonstrate a function of p53
that may underlie its role in tumor suppression.
INTRODUCTION
Recent advances in our understanding of the mechanisms pro-
tecting the integrity of human genome have led to the realization
that dysregulation of genome maintenance in cancer may leave
tumor cells vulnerable to chemotherapeutic approaches exploit-
ing genomic instability (Curtin, 2012; Lord and Ashworth, 2012).
Oncogenes and/or loss of tumor suppressor protein function
drive tumorigenesis by deregulating cell-cycle checkpoints,
DNA repair, and apoptotic pathways. This leads to cell prolifera-
tion that is achieved at the expense of replication stress, causing
DNA damage (Bartkova et al., 2005; Gorgoulis et al., 2005).
Replication stress is a crucial driver of genomic instability. Un-
repaired DNA lesions, secondary DNA structures, and encoun-132 Cell Reports 15, 132–146, April 5, 2016 ª2016 The Authors
This is an open access article under the CC BY-NC-ND license (http://ters with the transcription machinery may block the timely
progression of the replisome. This causes the stalling and
collapse of replication forks, leading to double-strand breaks
(DSBs) and recombinogenic DNA structures, driving deleterious
genome rearrangements. Analysis of early human precancerous
lesions reveals hallmarks of activated DNA damage signaling,
leading to a model whereby oncogene-induced hyperprolifera-
tion results in replication stress, increased DNA DSBs, and p53
induction, which poses a protective barrier against tumorigen-
esis (Halazonetis et al., 2008; Murga et al., 2011). It is thought
that oncogenes cause increased origin firing that ultimately re-
sults in the overall spatial and temporal deregulation of DNA
replication (Bester et al., 2011; Di Micco et al., 2006; Domi-
nguez-Sola et al., 2007).
An important downstream consequence of these alterations in
DNA replication is the potential for clashes with other processes
occurring on the DNA strand, particularly transcription, resulting
in replication fork collapse and DNA breaks. As a case in point,
cyclin E overexpression has recently been shown to specifically
increase transcription and replication interference, and the ef-
fects are ameliorated by inhibiting transcription (Jones et al.,
2013). Therefore, proper coordination of replication and tran-
scription is required during the S phase to avoid the risk of
DNA damage. However, the key molecular players in these pro-
cesses remain largely unidentified.
Although the p53 pathway is clearly central for genome main-
tenance, how it protects replicating DNA is not well understood.
p53 has a myriad of functions aimed at both protecting the cell
from genotoxic insult (pro-survival) and protecting the tissue
and organism from neoplasm (pro-apoptosis) (Cheok et al.,
2011; Lowe et al., 1993; Vousden and Prives, 2009). p53 im-
poses a senescence program or mediates cell-cycle arrest
following DNA damage and replication stress to allow the repair
of damaged DNA or to prevent further proliferation of damaged
cells (Bunz et al., 1999; Jackson et al., 2012; Taylor et al.,
1999). As a consequence, loss of p53, in conjunction with ATR
suppression, results in a deleterious gene interaction due to
the combined loss of G1 and S-G2 checkpoints (Nghiem et al.,
2001; Reaper et al., 2011). Therefore, p53 deficiency, due to
loss of a G1 checkpoint, leads to promiscuous S-phase entry
that confers increased genomic instability and cell lethalitycreativecommons.org/licenses/by-nc-nd/4.0/).
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when ATR is suppressed (Murga et al., 2009; Schoppy et al.,
2012; Toledo et al., 2011). In addition, loss of the G2 checkpoint
maintenance in p53-deficient cells also sensitizes them to
various forms of DNA damage (Bunz et al., 1998). However, it
is uncertain whether p53 could play a more direct role during
the S phase in ensuring replication integrity, which is indepen-
dent of its canonical roles in cell-cycle checkpoint arrest.
Here, we show that the loss of wild-type p53 sensitizes cells
toward topoisomerase (Topo) II poisons and results in increased
DNA damage and replication defects that are reversed by tran-
scription inhibition. We proposed that increased transcription-
replication collisions, occurring in the absence of p53, generate
elevated DNA torsional stress, which engages Topo II for resolu-
tion. We highlight an important role of p53, distinct from its
canonical roles in cell-cycle checkpoint control, in maintaining
genomic integrity and replication fidelity by preventing DNA
topological conflicts between transcription and replication.
RESULTS
Unbiased Screen Reveals that p53-Deficient Cells Are
Selectively Sensitive to Topo Inhibitors
p53 mutations are conventionally associated with resistance to
chemotherapy due to loss of pro-apoptotic pathways (Oren
and Rotter, 2010), but p53 deficiency has conversely been re-
ported to increase sensitivity to doxorubicin (Dox) (Bunz et al.,
1999), although the mechanism remains unclear. To delineate
the mechanism explaining the paradoxical increase in sensitivity
to Dox in p53-deficient cells, we performed an unbiased screen
on a pair of isogenic HCT116 colon carcinoma cell lines differing
only in p53 status (HCT116 p53+/+ and HCT116 p53/) (Bunz
et al., 1998), using a panel of 83 FDA (Food and Drug Administra-
tion)-approved drugs, for drugs behaving similarly to Dox and
thus identify common lesions that may sensitize p53-deficient
cells (Table S1).
We established a robust and quantitative cytometry-based
assay (differential fluorescence labeling of cells; DiFLC), to
compare the relative viability of cocultured fluorescently labeled
cells, the HCT116 p53+/+ (GFP) and p53/ (red fluorescent pro-
tein; RFP) cell lines, grown and treated under a single drug treat-
ment condition. Cocultures of HCT116 p53+/+ (GFP) andHCT116
p53/ (RFP) cells were screened using drug concentrations (le-
thal dose [LD]20–LD80) that would ensure effective cell killing
(Table S2) and avoid unspecific side effects. The Drug SensitivityFigure 1. Drug Screen Reveals that p53 Deficiency Is Synthetically Let
(A) DiFLC assay. Percentages of GFP (p53+/+) or RFP (p53/) cells normalized
normalized percent RFP ratios (Experimental Procedures). Corresponding DSI val
of each drug (Table S2) are represented in color map; DSI values < 0 (red) an
respectively. Asterisk indicates drug effects >100-fold sensitivity of RFP cells ov
(B) Drugs ranked by DSI values.
(C) Drug sensitivity validated with WST1 cell viability.
(D) HCT116 p53+/+ (GFP-labeled) cells stably transduced with lentiviral shVect
parental HCT116 p53+/+ cells, and treated with Dox for 24 hr. Percentage of
experiments were performed. WB validates p53 knockdown. UT, untreated.
(E) Dox-treated (for 24 hr) HCT116 and MCF10A p53+/+ and p53/ cells stained
Dox-treated wild-type HCT116 and MEFs and derivatives carrying homozygous
(F) TOP2A, TOP2B, and TOP1 WB in HCT116 cells.
Error bars indicate SD. See also Table S2.
134 Cell Reports 15, 132–146, April 5, 2016Index (DSI) (see Experimental Procedures) was determined from
relative percentages of each cell type 5 days post-drug-recovery
(Figure 1A). A positive DSI indicates that p53/ cells were more
sensitive to the drug, reflected in an increased GFP:RFP cell
ratio, while a negative DSI indicates that p53/ cells show
decreased drug sensitivity.
p53 deficiency enhanced sensitivity to Topo-targeting com-
pounds (Figures 1B and S1), resulting in high DSI values of
>0.5. These included Dox, its derivative daunorubicin (Dau), eto-
poside (Etop, orVP-16), teniposide (Teni, or VM-26), and mitox-
antrone (Figures 1B and S1), suggesting that Dox mainly acts
on Topo and not via DNA intercalation and reactive oxygen spe-
cies (Frederick et al., 1990; Kurz et al., 2004). As expected, p53
absence caused resistance to DNA-cytotoxic drugs, including
DNA crosslinkers, DSB-inducing agents, and microtubule poi-
sons, as previously reported (Bunz et al., 1999; Lowe et al.,
1993), further demonstrating that the increased sensitivity of
p53/ cells does not apply to all DNA-damaging drugs.
Treatment with Topo II inhibitors markedly decreased colony
survival and viability of HCT116 p53/ cells compared to
HCT116 p53+/+ cells (Figures 1C and S1). Over 90% of cells sur-
viving the highest concentration of Dox (0.2 mM) were p53+/+
(GFP) cells (Figures S2A–S2C). p53 knockdown using different
short hairpin (shRNA) constructs also resulted in a selective
depletion of cells in a DiFLc assay (Figures 1D and S2D). This
also resulted in a predominant G2/M arrest, similar to drug-
treated HCT116 p53/ cells (Figure S2E). In the human mam-
mary epithelial MCF10A cell line, isogenic p53/ cells were
markedlymore sensitive to Dox compared towild-type cells (Fig-
ure 1E). Mouse embryonic fibroblasts (MEFs) harboring a genetic
knockout of p53 gene were also greatly sensitized to Dox (Fig-
ure 1E), confirming that p53 loss specifically sensitizes cells of
different genetic backgrounds, origins, and species to toxicity
from Topo II inhibitors in vitro.
Lethal Phenotype Induced by Topo II Inhibitors Require
TOP2A but Not TOP2B
Both HCT116 p53+/+ and p53/ cells expressed comparable
amounts of all Topo I (TOP1), Topo IIa (TOP2A), and Topo IIb
(TOP2B) proteins, even with Dox treatment (Figure 1F). Thus,
the increased sensitivity to Topo poisons of p53/ cells cannot
be simply explained by differential expression of Topo targets.
TOP2A and TOP2B are known targets of Topo poisons in can-
cer treatment (Burgess et al., 2008), but only TOP2A is cell cyclehal with Topo Inhibitors
to DMSO controls. DSI values are log2 values of normalized percent GFP/
ues and fold sensitivity are indicated in the color scale bar. Two concentrations
d > 0 (green) indicate sensitization of p53 wild-type and p53-deficient cells,
er GFP cells. conc, concentration.
or or p53-specific shRNAs shp53.3, shp53.5, and shp53.6, co-cultured with
GFP-positive cells was assessed 5 days post-recovery. Three independent
with crystal violet 12 days post-recovery. Bottom panel: Bright-field images of
deletions of the p53 gene 5 days post-recovery.
(legend on next page)
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regulated and more abundant in the S- and G2/M phases (Heck
et al., 1988). Notably, small interfering RNA (siRNA) to TOP2A
partially rescues p53/ cells in both colony survival and DiFLC
assays in response to Dox, Teni, and Etop (Figure 2A; Fig-
ure S3A), confirming TOP2A as a key target for Topo II poisons
(Figure 2A). In contrast, TOP2B siRNA did not rescue viability
in p53/ cells (Figure S3B). As expected, TOP1 siRNA sensi-
tizes cells to the effects of Topo II inhibition by Dox (Figure 2A)
(Burgess et al., 2008).
Loss of p53 Stabilizes TOP2A-DNA Complexes Causing
DSBs
Topo inhibitors like Dox, Etop, and Teni act to stabilize the tran-
sient protein-DNA complex generated during Topo activity
causing potentially lethal DSBs. We analyzed the accumulation
of stabilized TOP2A-DNA complexes by fractionating cell ex-
tracts on CsCl gradients and detecting TOP2A protein by
dot-blot (Figure 2B). Nucleic acid measurements locate DNA-
containing fractions (fractions 2–7), while the TOP2A proteins
free from DNA were detected in fractions 9–15. As expected,
the DNA fractions in untreated controls contain low to unde-
tectable levels of TOP2A protein (Figure 2B). Endogenous
TOP2A accumulation in the DNA fractions represents stabilized
TOP2A-DNA complexes, which occur, to a greater extent in
HCT116 p53/ cells (Figure 2B), in response to treatment
with Topo II inhibitors but not with camptothecin, a known
TOP1 inhibitor. We demonstrate that a catalytic inhibitor of
Topo II (ICRF-193) recapitulates the effects of Topo II poisons
in p53/ cells (Figure 2B). Consistently, p53 knockdown using
either p53-specific shRNAs in A549 (Figure S3C) or siRNAs in
HCT116 (Figure 2C) cells caused an enrichment of TOP2A-
DNA complexes.
Using pulsed-field gel electrophoresis (PFGE) to precisely
assess DSBs induction, compared to wild-type cells, we
observed extensive DSBs in HCT116 p53/ cells treated with
Topo II poisons and a catalytic inhibitor ICRF193 (Figures 2D
and S3D), which is consistent with an increase in phosphorylated
H2AX (YH2AX) foci in p53/ cells (Figure 2E). A 24-hr time
course analysis revealed that DSBs never accumulated in wild-Figure 2. Preferential Stabilization of TOP2A-DNA Complexes in p53-D
(A) Crystal violet staining of Dox-treated HCT116 p53/ cells transfected with non
TOP2A and TOP1 knockdown.
(B) CsCl gradient fractionation in HCT116 cells separates DNA-bound from solub
(C) Dot-blot of HCT116 cells with p53 siRNA and NT siRNA. Bottom panel: WB v
(D) PFGE detection of DSBs in HCT116 cells treated with 1.25 mM Etop, 0.1 mM
detected as single DNA band, according to previous protocol (Experimental Pro
(E) Immunofluorescence of gH2AX in 0.1 mM Dox-treated cells. Scale bar, 10 mm
(F) PFGE of p53+/+ and p53/ MEFs. 0.1 or 0.2 mM Dox used for 24 hr or 48 hr.
(G) Immunofluorescence (IF) of gH2AX in 0.2 mM Teni-treated MEFs (wild-type [W
nuclei quantified by ImageJ. Statistical analysis was performed using Mann-W
percentile range. Upper bar represents 75–90 percentile range, and lower bar re
(H) Teni- or Dox-treated (for 24 hr) MEFs stained with crystal violet 5 days post-r
(I) Bright-field images of MEFs treated with 0.1 mM Teni or Dox 5 days post-reco
(J) Apoptotic cells were measured by annexin V positivity in MEFs 5 days post-r
mean ± SD.
(K) PFGE of 0.2 mM Teni-treated MEFs. *Marker lane.
(L) Dot-blot of 0.2 mM Teni-treated MEFs. 20 mg, 10 mg, 5 mg, and 2.5 mg of DNA
(M) WB of 0.2 mM Teni-treated MEFs. Low and high exposures are shown for pC
Error bars indicate SD.
136 Cell Reports 15, 132–146, April 5, 2016type cells to significant levels, whereas in p53-deficient cells,
extensive DSBs are detected even at earlier time points (Fig-
ure S4). To further prove that the effects of the drugs were spe-
cific to TOP2A, we generated a single-site mutation (K378Q) in
TOP2A that renders the TOP2A protein catalytically inactive
and able to form a stable protein-DNA complex (Figure S5A)
(Hu et al., 1998). As we predicted, the overexpression of
TOP2A-K378Q recapitulates the effects of Topo II poisons, re-
sulting in a pronounced stabilization of TOP2A-DNA complexes
in the absence of p53 (Figure S5).
We reproduced these results in MEFs: isogenic p53/ MEFs
accumulated more DSBs than wild-type MEFs upon drug treat-
ment (Figure 2F). To question whether the increased sensitivity
extends to cells containing a gain-of-function mutation in the
p53 gene, we derived MEFs from a transgenic mouse model of
the Li Fraumeni syndrome, which harbors a p53R172Hmutation,
corresponding to the p53R175H hotspot mutation in human can-
cers (Lang et al., 2004). Treatment of homozygous p53 mutant
MEFs with Teni resulted in a far greater accumulation of
gH2AX foci in replicating EdU (5-ethynyl-2-deoxyuridine)-posi-
tive cells, compared to wild-type MEFs (Figure 2G). The
observed differential damage in S-phase cells translates to a
dramatic loss of cell viability and accumulation of apoptotic cells
in p53R172H MEFs when compared to wild-type MEFs (Figures
2H–2J). We verified that the DNA damage and DSBs formed in
p53R172HMEFs (Figure 2K) resulted from amarked stabilization
of TOP2A-DNA complexes. TOP2A-DNA complexes were stabi-
lized to a far greater extent in p53R172H MEFs than in wild-type
MEFs (Figure 2L). Equivalent expression of TOP2A and TOP2B
proteins in wild-type and p53R172H MEFs was detected (Fig-
ure 2M). Stabilization of mutant p53 protein was observed in
p53R172H MEFs, as reported previously (Goh et al., 2011;
Lang et al., 2004; Olive et al., 2004). In line with our hypothesis
that replication stress is significantly elevated in p53 mutant
cells, phosphorylation on CHK1 (pCHK1) was strongly enriched
in Teni-treated p53R172H MEFs (Figure 2M). Basal phosphory-
lation on CHK1 was also enriched (Figure 2M), indicating the
presence of increased residual CHK1 signaling due to the muta-
tion of p53 gene.eficient Cells
-targeting (NT) siRNA or TOP1 and TOP2A siRNAs. Bottom panel: WB validates
le TOP2A protein. Dot-blot detects TOP2A protein.
alidates p53 knockdown.
Teni, and 0.2 mM Dox. (M) refers to Lambda Ladder PFG Marker. Broken DNA
cedures). UT, untreated.
. Pink arrows indicate cells with lower gH2AX intensity.
T] or p53R172H) in the presence of EdU. gH2AX (red) in EdU-positive (green)
hitney-Wilcoxon test. ***p < 0.001. Scale bar, 10 mm. Boxes indicate 25–75
presents 10–25 percentile range.
ecovery.
very.
ecovery. Drug concentration in micromolar. ****p < 0.0001. Error bars indicate
were used.
HK1.
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Figure 3. Topo II Inhibition Results in Repli-
cation-Associated DNA Breaks in p53-Defi-
cient Cells
(A) Percentages of mitotic cells with anaphase
bridges (pink arrows) quantified. Mean values ±
SD of three independent experiments. Error bars
indicate mean ± SD. Scale bar, 10 mm.
(B) FACS analysis in HCT116 cells cotreated with
9 mM CDK inhibitor RO3306 (CDKi) and 0.1 mM
Dox. DAPI-stained nuclei show absence of mitotic
cells.
(C) PFGE of HCT116 p53+/+, p53/, and shp53-
transfected p53+/+ cells co-treated with CDKi
(9 mM) and Dox (0.1 mM). Untreated (UT), CDKi
alone, and Dox alone were used as controls.
(D) Dot-blot of HCT116 cells treated with CDKi and
Dox or CDKi alone.
(E) IF of gH2AX and EdU in HCT116 cells treated
withEdUand0.2mMTeni for 3hr. IntensityofgH2AX
per nucleus was quantified by ImageJ. Sta-
tistical analysis usingMann-Whitney-Wilcoxon test.
****p < 0.0001. Scale bar, 10 mm. -ve, negative;
+ve, positive. Gray boxes indicate 25–75 percen-
tile range. Left bar represents 10–25 percentile
range, and right bar represents 75–90 percentile
range.
(F) PFGE of HCT116 p53/ cells co-treated with
aphidicolin and Dox or aphidicolin alone.
Error bars indicate SD.Loss of p53 Confers S-Phase-Specific DNA Damage
To distinguish whether the DNA breaks occur during failure of
proper chromosome segregation in mitosis or impaired reso-
lution of topological tensions in replication (Wang, 2002), we
used a CDK1 inhibitor (RO0336), to prevent mitotic entry.
Despite a significant increase in anaphase bridges in p53-defi-
cient cells with Dox (Figure 3A), which may suggest breaks in
mitosis, co-treatment with a CDK inhibitor, however, did not
suppress the majority of breaks in p53-deficient cells or in
cells stably expressing a p53 shRNA (Figures 3B and 3C).
Furthermore, CDK inhibition did not reduce the extent of
TOP2A-DNA complexes in p53/ cells when co-treated
with Dox (Figure 3D). These suggest that the majority of
damage-induced DNA breaks and TOP2-DNA complexes in
p53/ cells happen during DNA replication in S phase, not
from mitosis.
To determine whether such DNA damage originates from
S phase, we labeled replicating cells with EdU in the presence
of Teni and quantified gH2AX foci. A significant increase in
gH2AX intensity was observed in the EdU-positive p53-defi-
cient cells, suggesting S-phase damage (Figure 3E). Further-
more, aphidicolin, an inhibitor of DNA polymerase a, markedly
attenuated DSBs in p53-deficient cells (Figure 3F). Together,
our results clearly indicate that DNA damage in p53-deficientCcells arises during replication, and the
role that wild-type p53 plays in protect-
ing against Topo II inhibition during the
S phase is independent of its described
G2 checkpoint function in preventingmitotic entry and chromosomal breaks (Bunz et al., 1998,
1999; Nghiem et al., 2001).
Critical Function of p53 in Maintaining Genetic Stability
Is Independent of Its Canonical p21-Driven Cell-Cycle
Arrest
Our results indicate that the differential DNA damage in drug-
treated wild-type and p53-deficient cells is already apparent
in their respective S-phase population. Furthermore, we syn-
chronized isogenic HCT116 p53+/+, p53/, and p21/ cells
with hydroxyurea (HU) and analyzed TOP2A-DNA complexes
after recovery in Dox (Figure 4A). Even though all cells (wild-
type, p53/, and p21/) cycled through S phase in a
synchronized manner, only p53/ accumulated complexes
(Figure 4B), consistent with a selective decrease in viability
of p53/ cells in response to Topo II inhibitors (Figure 4C).
Together, our data indicate strongly that the p53-dependent
response to Topo II inhibitors do not require p21. We inferred
that the p21-dependent G1 checkpoint is also irrelevant to
p53’s function in mediating protection against Topo II inhibi-
tors, contrary to previous reporting (Bunz et al., 1999). To
further substantiate the point, we show that p21/ cells
are, indeed, defective in their DNA-damage-induced G1
checkpoint (Figure 4D), in response to 0.1 mM Dox, yetell Reports 15, 132–146, April 5, 2016 137
proficient in preventing damage from Topo II inhibitors. In
response to a lower dose of Dox (0.05 mM) that is insufficient
in activating a complete cell-cycle arrest, as evidenced by the
presence of bromodeoxyuridine (BrdU)-positive S-phase
cells, both HCT116 p21/ and p53+/+cells show comparable
cell-cycle profiles (Figures 4D and 4E), whereas a pronounced
G2 checkpoint arrest is evident in p53/ cells, most likely in
response to unresolved damage incurred during the S phase.
Western blot (WB) analysis revealed equivalent expression of
TOP2A protein in HCT116 p53+/+, p53/, and p21/ cells
(Figure 4F). To further convince ourselves that the wild-type
cells did not spontaneously arrest in G1 due to Dox, we
show, using co-treatment with nocodazole to block cells in
the G2/M phase, that all cells had cycled through the S phase
in the same treatment period (24 hr) with Dox, resulting in only
a G2/M peak (Figure S6).
Together, these data demonstrate an uncoupling between the
roles of p53 in maintaining genome stability in response to Topo
II inhibition and in G1 cell-cycle arrest.
Increased DNA Damage in p53-Deficient Cells Is Not
Due to Defective DNA Damage and Replication
Checkpoints
Topo II is thought to modulate DNA topology at sites of tran-
scription/replication interface and to bind promoters of tran-
scribed genes specifically in S phase (Bermejo et al., 2007,
2009). Hence, we asked whether our current observations
arose from aberrant transcription/replication events. Since the
replication checkpoint is important in counteracting abnormal
fork transitions and disassembling the RNAP II preinitiation
complex to prevent replication and transcription interference,
we first analyzed whether DNA damage (DDR) checkpoints
are intact in p53/ cells upon Topo II inhibition. Both wild-
type and p53-deficient cells display an increase in the colocal-
ization of 53BP1 and gH2AX foci (Figure 5A), surrogate markers
of the activation of the DNA DSB response, suggesting that
p53 loss did not affect the initiation of early DNA damage
signaling. Rather, an overall increase in 53BP1 and gH2AX
foci intensity was detected in p53-deficient cells (Figure 5A).
Similar kinetics of recruitment of ATR and ATM to the chro-
matin was observed in wild-type and p53-deficient cells
(Figure 5B). Increased phospho-Chk1 and phospho-Chk2 (Fig-
ure 5B) and enhanced recruitment of other DNA damage repair
proteins—namely, MRN complex (Mre11-Rad50-Nbs1) and
CtIP (Figure 5C), in the p53-deficient cells—suggest that wild-
type p53 plays a role in limiting DNA damage and check-
point activation. Interestingly, we observed an intense accumu-
lation of RNAPII (RNA polymerase II), together with TOP2A,
in the p53/ cells. This was also observed in p53-def-
icient MEFs, concomitant with the increased accumulation of
Mre11, Nbs1, and Rad51 (Figure 5D). However, TOP2B pro-
tein recruitment was similar, regardless of p53 status, further
proving that the genotoxicity in p53-deficient cells is specific
to that of TOP2A (Figure 5D). Together, the data suggest that
RNA transcription may be altered in the absence of p53, which
could result in increased DNA torsional stress, generating
substrates that require TOP2A activity at the chromatin to
resolve.138 Cell Reports 15, 132–146, April 5, 2016Transcription Creates DNA Topological Conflicts in
p53-Deficient Cells
To establish the involvement of transcription in increased
genomic instability seen in replicating p53/ cells, we inhibited
RNAPII-mediated transcription using a CDK inhibitor, DRB,
which blocks the elongation step of RNAPII transcription and
causes premature termination (Fraser et al., 1979). We observed
a significant reduction in DNA DSBs in HCT116 p53/ cells co-
treated with DRB and Teni, compared to Teni treatment alone
(Figure 6A), which corresponded to an increased colony survival
in cells similarly treated (Figure 6B), indicating thatRNA transcrip-
tion in the absence of p53 contributes to the genotoxicity of Teni.
Nomarked change in cell-cycle profile was associated with DRB
treatment (Figure 6C), eliminating the possibility that DRB may
cause a G1 arrest and so protect cells from S-phase damage
induced by Teni. Supporting the view that transcription elevates
DNA supercoiling in p53-deficient cells, we show that DRB treat-
ment greatly reduced TOP2A recruitment and TOP2A-DNA com-
plex formation (Figure 6D), protecting p53/ cells from the full
toxicity of Teni. Furthermore, we show that DRB affected neither
the expression of TOP2A protein nor a major replication stress-
induced protein kinase, ATR, even though it clearly reduced
phosphoCHK2 in p53-deficient cells (Figure 6E). Notably, DRB
decreased Teni-induced pCHK2 (Figure 6E) and gH2AX (Figures
6F and 6G) predominantly in p53-deficient cells, but its effect in
wild-type cells was marginal. This points to the presence of tran-
scription-dependent damage as a major source of genomic
instability in p53-deficient cells. Consistently, DRB reduces
Teni-induced gH2AX foci intensity in p53-deficient cells to a level
equivalent to that in Teni-treated wild-type cells. Together, our
data support themodel that dysregulation of replication and tran-
scription in p53-deficient cells causes topological conflicts, ex-
plaining the increased genotoxicity toward Topo II poisons.
In accordancewith ourmodel,wepredict that lossof p53might
elevate DNA replication defects. We took advantage of the DNA
fiber-labeling approach, which enables replication analysis on
single DNA molecules visualized by immunofluorescence (Fig-
ure 6H). DNA track lengths were measured using ImageJ.
Remarkably, p53 absence impaired normal fork progression,
resulting in a significant decrease in median track length from
12.05kb (n=110) inwild-typecells to 8.26kb (n=100) (Figure 6H).
Significantly, transcription inhibition by DRB restores DNA track
lengths in p53-deficient cells (8.32 kb; n = 100) to near wild-
type levels (11.8 kb; n = 130) but has marginal effects in wild-
type p53 cells, indicating that transcription impedes normal fork
progression in p53-deficient cells (Figure 6I). This is consistent
with our model that cells lacking p53 experience increased inter-
ference between replication and transcription, resulting in exten-
sive fork collapse and impaired replication fork progression.
Together, our data suggest that a major source of replication
stress in p53-deficient cells arises from transcription-associated
damage during S phase.
In Vitro Sensitivity to Topo II Inhibitors Translates in
In Vivo Tumor Xenografts
We tested the growth of HCT116 p53/ spheroids in response to
Dox, Etop, or Teni. Unlike wild-type cells, p53/ spheroids
showed more pronounced growth inhibition (Figures 7A and 7B).
D
ox
1Fraction no 2 3 4 5 6 7 8 9 10 11 12 13 14 15
U
ntreated
DNA bound TOP2A Soluble TOP2A
BA
C
ou
nt
PI
-/-
-/-
HU HU + Dox
p53
+/+
-/-
-/-
p53
p53
p21
+/+
-/-
-/-
p53
p53
p53
p21
p21
+/+
100
80
60
40
20
0
Dox Etop Teni
C
on
tro
l
p21
p53
-/-
-/-
 C1  C2   C3
P
er
ce
nt
ag
e 
of
 c
el
ls
 C
R
FP
Control Dox Etop Teni
p53-/-
29.2
25.7 43.6
3.5 8.2 3.4
22 74 34.4 57 32.5 64
GFP
p53+/+
p53+/+p21
-/-
 C1  C2   C3  C1  C2   C3
DAPI
Untreated
p53 p53 p21-/-+/+ -/-
FI
TC
C
ou
nt
s G1
S
G2/M
52.8% 54.4% 54.5%
0.05µM Dox
FI
TC
C
ou
nt
s
DAPI
G1
S
G2/M
15.7% 19.1% 24.7%
p53 p53 p21-/-+/+ -/-
0.1µM Dox 
FI
TC
C
ou
nt
s
DAPI
G1
S
G2/M
1.78% 3.07% 5.47%
p53 p53 p21-/-+/+ -/-
D
E F HCT116
p53
Untreated Dox 24h
TOP1
TOP2A
Actin
p21
-/- -/- -/- -/-
p53 p53 p21p21p53
+/+
p53
+/+
0 
20 
40 
60
80 
100 
Pe
rc
en
ta
ge
 o
f c
el
ls
 (%
) 
Ploidy 
G2 
S 
G1 
UT 0.1µM 0.05µM 
-/-
-/-
p53
p21
p53
+/+
A:
B:
C:
A    B   C A    B   C A    B   C
(legend on next page)
Cell Reports 15, 132–146, April 5, 2016 139
BD
C
A Figure 5. Intact DNA Damage Signaling and
DSB Repair in the Absence of p53
(A) Colocalization of gH2AX and 53BP1 foci. Scale
bar, 10 mm. Lower panel: Quantification by Im-
ageJ. Intensity units (per nucleus) are indicated
as a.u. Statistical analysis was performed using
Mann-Whitney-Wilcoxon test. UT, untreated.
***p < 0.001; ****p < 0.0001. Error bars indicate SD.
Boxes indicate 25–75 percentile range. Upper bar
represents 75–90 percentile range, and lower bar
represents 10–25 percentile range
(B) WB of chromatin fractions and whole-cell
lysates in 0.1 mM Dox-treated HCT116 cells.
(C) WB of TOP2A, RNAPII, CtIP andMRN complex
(Mre11-Rad50-Nbs1) in insoluble chromatin frac-
tions (HCT116).
(D) WB of TOP2A, RNAPII, Nbs1, Mre11, RAD51,
and TOP2B in insoluble chromatin fractions of
0.1 mM Dox-treated MEFs.To understand whether these effects could extend to in vivo con-
ditions, xenograft experiments were performed in nude mice.
A significant inhibition of tumor growth was observed in Dox-Figure 4. Wild-Type p53 Protects from Topo II Poisons through a Cell-Cycle-Arrest-Independe
(A) FACS (propidium iodide, PI) of HCT116 cells synchronized with 2 mM hydroxyurea (HU) and recovered in 0
(16 hr) shows cells synchronized at the G1/S phase.
(B) Dot-blot of HCT116 cells subjected to similar conditions as in (A). Untreated cells were used as controls
(C) DiFLC assays using HCT116 p53+/+ (GFP-labeled), HCT116 p53/ (RFP-labeled), and HCT116 p21/ (un
and C3) of each drug. Dox: 0.05, 0.1, and 0.2 mM; Etop: 1.25, 2.5, and 5 mM; Teni: 0.05, 0.1, and 0.2 mM
experiments. Right: representative FACS histograms showing percentages of each cell type in bold.
(D) FACS of HCT116 cells untreated or treated with 0.1 mM or 0.05 mM Dox. BrdU-positive population indicat
(E) Percentages of G1, S and G2/M cell population from (D) summarized in graph. UT, untreated.
(F) WB of TOP1 and TOP2A in untreated and Dox (0.1-mM)-treated HCT116 cells.
140 Cell Reports 15, 132–146, April 5, 2016treated nude mice bearing HCT116
p53/ xenografts but not in untreated
mice or those bearing p53+/+ xenografts
(Figure 7C). Kaplan-Meier survival analysis
revealed that while all animals bearing
p53+/+ xenografts had reached endpoint
(tumors > 800 mm3) by day 50, only half
of the mice in the p53/ xenograft group
receiving the higher drug dose reached
endpoint (Figure 7D). Markedly, more
cleaved caspase-3 was detected in
p53/ xenografts treated with Dox (Fig-
ure 7E). Similarly abundant caspase-3 ac-
tivity was detected in HCT116 p53/
cells, but not in HCT116 p53+/+ cells
in vitro (Figure 7F). Together, these data
show that the heightened toxicity of Topo
II inhibitors for p53/ tumor cell lines
in vitro also extends their effects in vivo in
a controlled setting.
DISCUSSION
Wild-type p53 elicits a checkpoint arrest
to block promiscuous S-phase entry orpremature mitosis in response to ATR/CHK1 inhibition or other
replication inhibitors (Nghiem et al., 2001). However, any role
that p53 plays beyond its checkpoint functions in preventingnt Function
.1 mMDox for 8 hr (HU + Dox). HU treatment alone
.
labeled) treated with three concentrations (C1, C2,
; Graph represents averages from at least three
es S-phase cells. FITC, fluorescein isothiocyanate.
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destabilizing replication stress is still unknown. Uncoordinated
unwinding of the DNA by RNA and DNA polymerases results in
topological conflicts during replication that could lead to DSBs
and aberrant recombinogenic events (Azvolinsky et al., 2009;
Helmrich et al., 2011). Topo II is thought to modulate DNA topol-
ogy at the interface between transcription and replication (Ber-
mejo et al., 2007, 2009). Here, in our in-depth investigations of
the function of p53 in conferring ‘‘resistance’’ to Topo II inhibi-
tion, we used a multitude of experimental systems and isogenic
cell lines to carefully dissect the checkpoint dependency and to
eliminate mechanisms known to confer p53-dependent protec-
tion from DNA damage. Our data, instead, support the paradigm
that p53 plays a critical role in ensuring replication integrity by
preventing transcription-replication collisions and DNA topolog-
ical conflicts, a role that may be critical for its function in tumor
suppression.
The unexplained paradoxical observation that cells are
sensitized to Dox (Bunz et al., 1999), despite the loss of p53-
dependent apoptotic response, prompted us to investigate the
unknown underlying mechanism. Here, we greatly extended
this observation, using a systematic drug screening approach
to identify common damaging lesions that may sensitize p53-
deficient cells. We found that p53-deficient cells are sensitized
not just to Dox but also to all Topo II poisons. Stabilization of
TOP2A-DNA complexes is responsible for the observed geno-
toxicity in p53-deficient cells, and even in isogenic cells
harboring a gain-of-function (GOF) mutation of p53 commonly
found in human cancers, counter-intuitive to the expectation
that GOF p53mutation should confer resistance to DNA damage
and promote cell survival (Oren and Rotter, 2010).
Although we demonstrate that the in vitro sensitivity to Topo II
poisons translates into better therapeutic efficacy of p53-defi-
cient tumor xenografts, the clinical response to Topo II poisons
is a more complex integration of various other factors that may
influence drug response including, for example, gain of MDR
(multi-drug resistance genes) (Gottesman et al., 2002), altered
homologous recombination efficiency (Treszezamsky et al.,
2007), decreased repair of TOP2-DNA cleavage adducts (Cortes
Ledesma et al., 2009), or altered TOP2A expression (Burgess
et al., 2008). Therefore, a thorough investigation of these factors
that may influence the efficacy of Topo II poisons is needed for
an accurate prediction of treatment outcome. Recently, the
large-scale integration of genomic data and cell-line drug sensi-
tivity data in the Genomics of Drug Sensitivity in Cancer (GDSC)Figure 6. Dysregulation of Transcription and Replication Processes M
(A) PFGE of HCT116 p53/ cells co-treated for 24 hr with Teni and DRB. UT, Te
(B) Crystal violet staining of HCT116 p53/ cells treated with Teni and DRB. Ten
(C) FACS (PI) of HCT116 p53/ cells treated with Teni, with or without DRB (20
(D) Dot-blot of HCT116 p53/ cells co-treated with Teni (0.2 mM) and DRB (20 m
(E) RNAPII, TOP2A, pCHK2, ATR, and b-actin detected in whole-cell lysates.
(F) gH2AX (IF) in cells treated with 0.2 mM Teni with or without DRB for 3 hr. Sca
(G) Distribution of gH2AX foci intensity from (F). Horizontal lines: mean values.
p values are indicated.
(H) Single-molecule analysis of DNA replication. Insert shows a single DNA fiber lab
(IdU, green). Red or green arrows indicate orientation of fork progression. DNA fi
Median track length and number of fiber values (n) are indicated. Statistical anal
(I) Median track length in HCT116 cells pre-treated with 20 mMDRB (1 hr) quantifie
Error bars indicate SD. Boxes indicate 25–75 percentile range. Left bar represen
142 Cell Reports 15, 132–146, April 5, 2016database combines cell-line drug response studies to predict
biomarkers influencing drug response (Garnett and McDermott,
2012). In the GDSC database, p53 genetic status marginally in-
fluences etoposide sensitivity, with drug resistance being corre-
lated with p53 mutation. This cautions that other factors could,
indeed, modulate response to Topo II poisons, although the
screening methodology (for example, assessing short-term
versus longer term cell viability) could also influence the conclu-
sions on drug-gene relationships.
Despite other known effects of Dox, we show that it acts on
Topo II and causes S-phase damage in p53-deficient cells,
providing us with the first set of hints that p53 renders some pro-
tective effect in S phase. By carefully dissecting the p21-depen-
dent and p21-independent roles of p53, we found that themech-
anistic role of wild-type p53 in response to Topo II inhibition is an
S-phase phenomenon, not mediated through a p21-driven G1/S
arrest, since p21/ cells phenocopy wild-type cells (Figures 4B
and 4C). Further evidence to substantiate the protective role of
p53 in theS-phase is as follows: first, thedifferential DNAdamage
in wild-type and p53/ cells is apparent predominantly in their
S-phase population, detectable by EdU/gH2AX positivity (Fig-
ure 3E); second, DSBs that accumulated in p53-deficient cells
are not a consequence of chromosomal breaks from chromo-
somal missegregation events during mitosis but, rather, are a
result of replication processes and are attenuated by aphidicolin
(Figure 3F). Third, comparison of DNAdamage immediately upon
completion of S phase, following a short timed-release of cells
from HU-induced G1/S arrest into Dox shows that TOP2A-DNA
complexes are differentially formed in wild-type and p53/ cells
(Figures 4Aand4B). Altogether, our data support a previously un-
characterized function of wild-type p53 in preventing topological
problems and maintaining S-phase integrity.
Althoughmanynewplayers, includingBRCA1andDICER,have
been recently reported tomaintain genomic integrity by regulating
replication-transcription coordination (Castel et al., 2014; Hatchi
et al., 2015), a role for p53 in this context has not been described
hitherto. We suggest that p53 prevents replication-transcription
collisions, therebymaintaining genomic stability duringDNA repli-
cation. Consistent with this, we show that pharmacologic inhibi-
tion of transcription decreases TOP2A-DNA complexes, at-
tenuates Topo-II-poison-induced DSBs and DNA damage, and
partially restores the viability of p53-deficient cells. Our results
imply that, in the absence of p53, increased topological conflicts
created by transcription and replication collisions create a siteay Be Alleviated by Inhibition of Transcription
ni alone or DRB alone was used as controls.
i alone was used as control. Error bars indicate mean ± SD.
mM). UT, untreated.
M). Teni alone was used as control. 15 mg, 7.5 mg, and 3.75 mg of DNA loaded.
le bars, 10 mm.
Statistical analysis was performed using Mann-Whitney-Wilcoxon test. The
eledwith 15min chloro-deoxyuridine (CldU, red) and 15min iodo-deoxyuridine
ber track length quantified by ImageJ. Box represents 25–75 percentile range.
ysis was performed using Mann-Whitney-Wilcoxon test. ****p < 0.0001.
d in graph. Statistical analysis usingMann-Whitney-Wilcoxon test. ***p < 0.001.
ts 10–25 percentile range, and right bar represents 75–90 percentile range.
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of action for TOP2A. Excessive torsional stress that accumulates
may further impede replication processes.
A rational prediction of the aforementioned model is that repli-
cation defects are increased in p53-deficient cells. We found that
replication fork progression is impaired in the absence of p53,
even with the lack of exogenous DNA damage, suggesting that
p53 acts within S phase normally to prevent DNA damage from
occurring. An overall decrease in the measured DNA fiber track
lengths in p53-deficient cells may occur as a result of extensive
multiple replication fork collapse due to pervasive transcription
interfering with replication fork progression. In line with this, tran-
scription inhibition restores replication fork progression in p53-
deficient cells and not in wild-type cells, thus providing compel-
ling evidence that transcription contributes to chronic replication
stress in the absence of wild-type p53 functions.
Our data support a paradigm shift in our understanding of
p53’s role in tumor suppression. We propose that an important
primary function of p53, distinct from its canonical response to
acute DNA damage, is to prevent the initiation of transcription-
associated DNA damage and replication stress and protect
against a dangerous source of endogenous DNA damage—
namely, DNA replication. The pronounced selective sensitivity
of p53-deficient cells specifically to Topo II poisons, and not to
other DNA-damaging agents that directly cause DNA breaks,
suggests that the p53-dependent response to endogenous repli-
cation stress is mechanistically different from that stimulated by
acute exogenous DNAdamage. Indeed, p53’s response to acute
DNA damage in tumor suppression has been widely debated.
Acute p53 response to DNA damage was found not to contribute
to p53-mediated tumor suppression in mice (Christophorou
et al., 2006). Furthermore, murine models demonstrated that
much of p53’s transcriptional activity, as well as its functions in
cell-cycle arrest and apoptosis, are dispensable for its tumor-
suppressive functions (Brady et al., 2011; Li et al., 2012; Valente
et al., 2013). Here, we present models to explain how p53 may
guard the genome by preventing replication-dependent dam-
age. A possibility is that p53 acts directly at the replication fork
mediating fork transition and avoiding clashes with transcription
complexes. Interestingly, p53 has been suggested to bind
in vitro to replication forks to promote fork regression (Subrama-
nian and Griffith, 2005), hence raising a possibility that, in cells,
p53 may promote fork regression and decrease topological ten-
sions upon any impediments to replication. Another possibility is
that p53 may be required for the spatial and temporal regulation
of transcription. Absence of p53 may lead to failure of proper
timely regulation of transcription. In line with its reported activityFigure 7. Preferential Drug Treatment Efficacy for p53-Deficient Tumo
(A) Growth of HCT116 3D spheroids monitored days after recovery from 80 nM T
(B) Graphic measurements of spheroids. Mean values ± SD of three to five samp
(C) Tumor volume (in cubic millimeters) in mice measured after first day of dru
calculated.
(D) Kaplan-Meier statistical analysis of tumor growth delay. Endpoint taken as th
(E) Immunohistochemistry of cryosections of tumor xenografts using cleaved ca
(F) Caspase-3 activity detected in HCT116 cells using a luminescence-based ce
detected usingWST1 proliferation reagent and expressed as fold increase over un
450 nm.
Error bars indicate mean ± SD. mpk, mg per kg.
144 Cell Reports 15, 132–146, April 5, 2016in transcription repression (Murphy et al., 1999), one likely sce-
nario in which p53 may act is to regulate transcription through
reversibly suppressing transcription and avoiding unintended
clashes with the replication machinery.
Our study reveals an intriguing aspect of p53-dependent
response to counteract S-phase-imposed genotoxicity by pre-
venting genetic instability arising from replication/transcription
processes, thus preserving overall genomic integrity and pro-
moting cell survival. The proposed function of p53 has far-reach-
ing implications for its role as a tumor suppressor. We suggest
that the failure to regulate conflicts between replication and tran-
scription in cells with nonsense or missense mutations of p53
could contribute, in part, to the increased genomic instability
that eventually promotes malignant transformation.
EXPERIMENTAL PROCEDURES
Co-culture Drug Screen and Calculation of the DSI
Drug titrations and WST1 cell viability assay were performed 5 days after drug
recovery to establish IC50 (50% inhibition of growth) and LD20–LD80 (LDs re-
sulting in 20%–80% viability) (Table S2). 1 3 104 of GFP and RFP cells were
treatedwith various concentrations of drugs for 24 hr (or as indicated). Fluores-
cence-activated cell sorting (FACS) analysis (BD LSR II System BD Biosci-
ences) was conducted to measure the percentage of GFP or RFP cells
5 days after drug recovery. Percentages of GFP cells (Y0) and RFP cells (X0)
in DMSO-treated controls and percentages of GFP cells (Yd) and RFP cells
(Xd) in drug-treated samples were determined. The ratio of Y
0 (Y0 = Yd/Y0)
over X0 (X0 = Xd/X0) defines the DSI (DSI = log2[Y0/X0]), in which percentages
of GFP or RFP cells in drug-treated samples were normalized to the DMSO
controls in each experiment. Positive DSI value indicates increased drug
sensitivity of HCT116 p53/ (RFP) cells over HCT116 p53+/+ (GFP) cells.
Dot-Blot Assay for Detection of TOP2A-DNA Complexes
The assay was optimized based on previously published protocols (Hartsuiker
et al., 2009). Cells were lysed in 1% sarkosyl/10 mM Tris-EDTA (TE) buffer
(pH 8.0), added to cesium chloride (MP Biomedicals) gradients, and ultracen-
trifuged at 150,000 rpm 3 g (Beckman Coulter) in a SW41 Rotor (Sorvall) at
25C for 16 hr. Fractions were extracted, and DNA concentrations were deter-
mined using the PicoGreen assay (Life Technologies). Peak DNA-containing
fractions were identified to normalize loading. The dot-blot assay was carried
out in a Bio-Dot Apparatus (Bio-Rad), and samples were captured onto a
0.45-mM nitrocellulose membrane (Bio-Rad) that was blocked in 5% milk/
PBST (PBS with Tween 20) before WB detection with antibodies.
PFGE
Cells were resuspended to a concentration of 106 cells per milliliter and
mixed with an equal volume of molten 2% LMP (Low Melting Point) Agarose
(Promega) before adding to plug molds (BioRad, 1703706) that were left
to solidify at 4C. Plugs were incubated in lysis buffer—100 mM EDTA
[pH 8.0], 0.2% sodium deoxycholate (w/v), 1% sodium lauryl sarcosiners
eni, 1.25 mM Etop, or 0.2 mM Dox.
les. vol, volume.
g administration (Day 0), at indicated time points. Mean tumor volume was
e time required for each tumor to reach 800 mm3.
spase-3 antibody.
llular assay (Caspase-Glo 3/7, Promega). Readings normalized to cell viability
treated cells. Mean values ± SD of three experiments. OD450, optical density at
(w/v)—at 37C for 36–72 hr and then in washing buffer (20 mM Tris-HCL,
50 mM EDTA [pH 8.0]). Plugs were run on a 0.9% Pulsed Field Certified
Agarose (BioRad, 162-0137) Tris-borate-EDTA (TBE) gel for 20 hr at 14C,
using the BioRad CHEF Mapper system. Gel running conditions were opti-
mized to detect the migration of broken DNA as a single DNA band in gel ac-
cording to previous protocol (Ray Chaudhuri et al., 2012). Gel was incubated
with SYBR Gold Nucleic Acid Gel Stain (Invitrogen) and imaged using an Uvi-
tec Cambridge imager. The marker used was Lambda Ladder PFG Marker
(New England Biolabs).
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